Gene expression analysis reveals functional pathways of glatiramer acetate activation

Expert Opinion on Therapeutic Targets

Volumn 17, Issue 4, 2013, Pages 351-362

  Bakshi, Shlomo ^a   Chalifa Caspi, Vered ^b   Plaschkes, Inbar ^b   Perevozkin, Igor ^a   Gurevich, Michael ^c   Schwartz, Riki ^a  

^a TEVA PHARMACEUTICALS   (Israel)

^b BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^c SHEBA MEDICAL CENTER   (Israel)

Author keywords

Functional pathways; Gene expression; Glatiramer acetate; Glatiramoid; Microarray; T cells

Indexed keywords

CALGRANULIN A; CALGRANULIN B; CXCL2 CHEMOKINE; CXCL3 CHEMOKINE; GAMMA INTERFERON; GLATIRAMER; INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 17F; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 4; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MANNITOL; TRANSCRIPTION FACTOR GATA 3; TRANSCRIPTION FACTOR T BET;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIGEN PRESENTING CELL; ARTICLE; B LYMPHOCYTE; CELL ACTIVATION; CELL DIFFERENTIATION; CELL STIMULATION; COMPARATIVE STUDY; CONTROLLED STUDY; DOWN REGULATION; DRUG ACTIVATION; EFFECTOR CELL; EX VIVO STUDY; FEMALE; GENE EXPRESSION PROFILING; GENE OVEREXPRESSION; HELPER CELL; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IMMUNOSTIMULATION; INFLAMMATION; LYMPHOCYTE PROLIFERATION; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; SPLEEN CELL; T LYMPHOCYTE; TRANSCRIPTION INITIATION; UPREGULATION;

ANIMALS; ANTIGEN-PRESENTING CELLS; CELL DIFFERENTIATION; CELL PROLIFERATION; CELLS, CULTURED; CHIMERA; DRUGS, GENERIC; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; IMMUNOSUPPRESSIVE AGENTS; LYMPHOCYTE ACTIVATION; MICE; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PEPTIDES; SPLEEN; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES;

EID: 84875189394     PISSN: 14728222     EISSN: 17447631     Source Type: Journal    
DOI: 10.1517/14728222.2013.778829     Document Type: Article

References (42)

1. Copaxone- (glatiramer acetate injection). Teva Pharmaceutical Industries, Ltd; Petach-Tikva, Israel; 2009
2. Varkony H, Weinstein V, Klinger E, et al. The glatiramoid class of immunomodulator drugs. Expert Opin Pharmacother 2009;10:657-68
3. Schori H, Kipnis J, Yoles E, et al. Vaccination for protection of retinal ganglion cells against death from glutamate cytotoxicity and ocular hypertension: Implications for glaucoma. Proc Natl Acad Sci USA 2001;98:3398-403
4. Kipnis J, Schwartz M. Dual action of glatiramer acetate (Cop-1) in the treatment of CNS autoimmune and neurodegenerative disorders. Trends Mol Med 2002;8:319-23
5. Teitelbaum D, Aharoni R, Arnon R, Sela M. Specific inhibition of the T-cell response to myelin basic protein by the synthetic copolymer Cop 1. Proc Natl Acad Sci USA 1988;85:9724-8
6. Putheti P, Soderstrom M, Link H, Huang YM. Effect of glatiramer acetate (Copaxone) on CD4+CD25high T regulatory cells and their IL-10 production in multiple sclerosis. J Neuroimmunol 2003;144:125-31
7. Stadelmann C, Kerschensteiner M, Misgeld T, et al. BDNF and gp145trkB in multiple sclerosis brain lesions: Neuroprotective interactions between immune and neuronal cells? Brain 2002;125:75-85
8. Ford C, Goodman AD, Johnson K, et al. Continuous long-term immunomodulatory therapy in relapsing multiple sclerosis: Results from the 15-year analysis of the US prospective open-label study of glatiramer acetate. Mult Scler 2010;16:342-50
9. Aharoni R, Teitelbaum D, Arnon R, Sela M. Copolymer 1 acts against the immunodominant epitope 82-100 of myelin basic protein by T cell receptor antagonism in addition to major histocompatibility complex blocking. Proc Natl Acad Sci USA 1999;96:634-9
10. Arnon R, Aharoni R. Mechanism of action of glatiramer acetate in multiple sclerosis and its potential for the development of new applications. Proc Natl Acad Sci USA 2004;101(Suppl 2):14593-8
11. Teitelbaum D, Aharoni R, Sela M, Arnon R. Cross-reactions and specificities of monoclonal antibodies against myelin basic protein and against the synthetic copolymer 1. Proc Natl Acad Sci USA 1991;88:9528-32
12. Webb C, Teitelbaum D, Arnon R, Sela M. In vivo and in vitro immunological cross-reactions between basic encephalitogen and synthetic basic polypeptides capable of suppressing experimental allergic encephalomyelitis. Eur J Immunol 1973;3:279-86
13. Duda PW, Krieger JI, Schmied MC, et al. Human and murine CD4 T cell reactivity to a complex antigen: Recognition of the synthetic random polypeptide glatiramer acetate. J Immunol 2000;165:7300-7
14. Duda PW, Schmied MC, Cook SL, et al. Glatiramer acetate (Copaxone) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis. J Clin Invest 2000;105:967-76
15. Brenner T, Arnon R, Sela M, et al. Humoral and cellular immune responses to copolymer 1 in multiple sclerosis patients treated with Copaxone. J Neuroimmunol 2001;115:152-60
16. Aharoni R, Teitelbaum D, Sela M, Arnon R. Copolymer 1 induces T cells of the T helper type 2 that crossreact with myelin basic protein and suppress experimental autoimmune encephalomyelitis. Proc Natl Acad Sci USA 1997;94:10821-6
17. Gran B, Tranquill LR, Chen M, et al. Mechanisms of immunomodulation by glatiramer acetate. Neurology 2000;55:1704-14
18. Wiesemann E, Klatt J, Wenzel C, et al. Correlation of serum IL-13 and IL-5 levels with clinical response to Glatiramer acetate in patients with multiple sclerosis. Clin Exp Immunol 2003;133:454-60
19. Aharoni R, Teitelbaum D, Sela M, Arnon R. Bystander suppression of experimental autoimmune encephalomyelitis by T cell lines and clones of the Th2 type induced by copolymer 1. J Neuroimmunol 1998;91:135-46
20. Aharoni R, Kayhan B, Eilam R, et al. Glatiramer acetate-specific T cells in the brain express T helper 2/3 cytokines and brain-derived neurotrophic factor in situ. Proc Natl Acad Sci USA 2003;100:14157-62
21. Miller A, Shapiro S, Gershtein R, et al. Treatment of multiple sclerosis with copolymer-1 (Copaxone): Implicating mechanisms of Th1 to Th2/Th3 immune-deviation. J Neuroimmunol 1998;92:113-21
22. Neuhaus O, Farina C, Yassouridis A, et al. Multiple Sclerosis: Comparison of copolymer-1-reactive T cell Lines from treated and untreated subjects reveals cytokine shift from T helper 1 to T helper 2 cells. Proc Nat Acad Sci USA 2000;97:7452-7
23. Venken K, Hellings N, Broekmans T, et al. Natural naive CD4+CD25 +CD127low regulatory T cell (Treg) development and function are disturbed in multiple sclerosis patients: Recovery of memory Treg homeostasis during disease progression. J Immunol 2008;180:6411-20
24. Haas J, Korporal M, Balint B, et al. Glatiramer acetate improves regulatory T-cell function by expansion of naive CD4(+)CD25(+)FOXP3(+)CD31(+) T-cells in patients with multiple sclerosis. J Neuroimmunol 2009;216:113-17
25. Hong J, Li N, Zhang X, et al. Induction of CD4+CD25+ regulatory T cells by copolymer-I through activation of transcription factor Foxp3. Proc Natl Acad Sci USA 2005;102:6449-54
26. Weber MS, Prod'homme T, Youssef S, et al. Type II monocytes modulate T cell-mediated central nervous system autoimmune disease. Nat Med 2007;13:935-43
27. Dunning MJ, Smith ML, Ritchie ME, Tavare S. beadarray: R classes and methods for Illumina bead-based data. Bioinformatics 2007;23:2183-4
28. Gene Expression Omnibus. Avaialble from http://www.ncbi.nlm.nih.gov/geo/ [Accessed 14 January 2013]
29. Ingenuity Pathways Analysis (IPA) Suite. Available from: Www.ingenuity.com [Accessed 14 January 2013]
30. Xu D, Chan WL, Leung BP, et al. Selective expression and functions of interleukin 18 receptor on T helper (Th) type 1 but not Th2 cells. J Exp Med 1998;188:1485-92
31. Jee Y, Piao WH, Liu R, et al. CD4(+) CD25(+) regulatory T cells contribute to the therapeutic effects of glatiramer acetate in experimental autoimmune encephalomyelitis. Clin Immunol 2007;125:34-42
32. Dhib-Jalbut S, Chen M, Said A, et al. Glatiramer acetate-reactive peripheral blood mononuclear cells respond to multiple myelin antigens with a Th2-biased phenotype. J Neuroimmunol 2003;140:163-71
33. Maron R, Slavin AJ, Hoffmann E, et al. Oral tolerance to copolymer 1 in myelin basic protein (MBP) TCR transgenic mice: Cross-reactivity with MBP-specific TCR and differential induction of antiinflammatory cytokines. Int Immunol 2002;14:131-8
34. Chen M, Gran B, Costello K, et al. Glatiramer acetate induces a Th2-biased response and crossreactivity with myelin basic protein in patients with MS. Mult Scler 2001;7:209-19
35. Franciotta D, Zardini E, Bergamaschi R, et al. Interferon gamma and interleukin 4 producing T cells in peripheral blood of multiple sclerosis patients undergoing immunomodulatory treatment. J Neurol Neurosurg Psychiatry 2003;74:123-6
36. Weder C, Baltariu GM, Wyler KA, et al. Clinical and immune responses correlate in glatiramer acetate therapy of multiple sclerosis. Eur J Neurol 2005;12:869-78
37. Sanna A, Fois ML, Arru G, et al. Glatiramer acetate reduces lymphocyte proliferation and enhances IL-5 and IL-13 production through modulation of monocyte-derived dendritic cells in multiple sclerosis. Clin Exp Immunol 2006;143:357-62
38. Wang Z, Hong J, Sun W, et al. Role of IFN-gamma in induction of Foxp3 and conversion of CD4+. J Clin Invest 2006;116:2434-41
39. Tennakoon DK, Mehta RS, Ortega SB, et al. Therapeutic induction of regulatory, cytotoxic CD8+ T cells in multiple sclerosis. J Immunol 2006;176:7119-29
40. Praksova P, Stourac P, Bednarik J, et al. Immunoregulatory T cells in multiple sclerosis and the effect of interferon beta and glatiramer acetate treatment on T cell subpopulations. J Neurol Sci 2012;319:18-23
41. Achiron A, Feldman A, Gurevich M. Molecular profiling of glatiramer acetate early treatment effects in multiple sclerosis. Dis Markers 2009;27:63-73
42. Citizen Petition. Document ID: FDA-2009-P-0555-0001. Docket ID: FDA-2009-P-0555-0001. Available from: Http://www.regulations.gov/#! documentDetail;D=FDA-2009-P-0555-0001 [Accessed 11 February 2011]